Published online before print February 7, 2008

This Article Full Text Full Text (PDF) All Versions of this Article: ajpath.2008.070601v1 172/3/628    most recent Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ninichuk, V. Articles by Anders, H.-J. Search for Related Content PubMed PubMed Citation Articles by Ninichuk, V. Articles by Anders, H.-J.

(American Journal of Pathology. 2008;172:628-637.)
© 2008 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2008.070601

Late Onset of Ccl2 Blockade with the Spiegelmer mNOX-E36–3'PEG Prevents Glomerulosclerosis and Improves Glomerular Filtration Rate in db/db Mice

Volha Ninichuk^*, Sebastian Clauss^*, Onkar Kulkarni^*, Holger Schmid^*, Stephan Segerer^*, Ewa Radomska^*, Dirk Eulberg, Klaus Buchner, Norma Selve, Sven Klussmann and Hans-Joachim Anders^*

From the Nephrological Center,^*Medical Policlinic, University of Munich, Munich; and NOXXON Pharma AG,Berlin, Germany

Diabetic kidney disease is associated with monocyte chemoattractant CC chemokine ligand 2 (CCL2)-dependent glomerular and interstitial macrophage recruitment. In addition, nephropathy is delayed in Ccl2 mutant diabetic mice. However, whether the late onset of therapeutic Ccl2 blockade modulates the progression of advanced diabetic nephropathy remains unknown. We addressed this question by antagonizing Ccl2 with mNOX-E36–3'PEG, an anti-Ccl2 L-enantiomeric RNA aptamer (ie, a Spiegelmer), which binds murine Ccl2 and blocks the recruitment of ex vivo-labeled macrophages to the kidneys of db/db mice with type 2 diabetes. We injected mNOX-E36–3'PEG subcutaneously at a dose of 50 mg/kg three times per week into uninephrectomized (1K) db/db mice with advanced glomerulopathy from 4 to 6 months of age. mNOX-E36–3'PEG reduced the number of glomerular macrophages by 40% compared with nonfunctional (control) Spiegelmer-treated 1K db/db mice. This result was associated with protection from diffuse glomerulosclerosis and significantly improved the glomerular filtration rate. mNOX-E36–3'PEG also reduced renal Ccl2 mRNA and protein expression compared with control Spiegelmer-treated 1K db/db mice of the same age. Together, the late onset of therapeutic Ccl2 blockade, eg, with specific Spiegelmers, offers protection from diffuse glomerulosclerosis in type 2 diabetic db/db mice and, thus, may represent a novel therapeutic strategy for advanced glomerulosclerosis.